Joint Rehab and Sports Medical Center
- PRP Therapy
- Arthritis Treatment
- Hormone Replacement Therapy (HRT)
- Testosterone Replacement Therapy (TRT)
- Stem Cell Therapy
Los Angeles, CA
Stem Cell Therapy clinics in Los Angeles
Los Angeles is one of the largest regenerative medicine markets in the country. The city combines world-class orthopedic and sports medicine specialists, research programs at Cedars-Sinai, UCLA Health, and Keck Medicine of USC, and a wellness culture that has driven steady patient demand across orthopedic, neurological, and longevity applications.
The range of providers here is wide, from hospital-affiliated research programs running FDA-authorized trials to private clinics offering autologous and allogeneic protocols under California's stem cell disclosure rules. Every clinic listed below has been reviewed against our vetting criteria, including federal provider registry checks, licensure, and treatment scope.
AMA Regenerative Medicine & Skincare
- Ozone Therapy
- IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Hyperbaric Oxygen Therapy (HBOT)
- Oxygen Therapy
Advanced BioCell
- Ozone Therapy
- Arthritis Treatment
- Lyme Disease Treatment
- Red Light Therapy
- Peptide Therapy
Dr. Bob Baravarian, DPM Podiatrist
- PRP Therapy
- Shockwave Therapy
- Arthritis Treatment
- Cryotherapy
- Stem Cell Therapy
Dr. Padra Nourparvar Stem Cell & PRP Institute of L.A.
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- PRP Therapy
- Shockwave Therapy
MD on staff
Bio-identical Hormone Replacement Therapy & Weight Loss
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Hyperbaric Oxygen Therapy (HBOT)
Cryohealthcare
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Arthritis Treatment
Regulatory context
A note on California's stem cell therapy rules.
California cellular therapy providers are subject to 21 CFR Part 1271. Minimally manipulated human cells, tissues, and cellular and tissue-based products used for homologous use are regulated under Section 361 without premarket approval. Products that are more than minimally manipulated, used non-homologously, or combined with a drug or device are regulated as biologics under Section 351 and require an IND for clinical use or a BLA for marketing. Adipose-derived stromal vascular fraction, culture-expanded mesenchymal stem cells, and exosomes used for orthopedic, cosmetic, neurologic, and longevity indications are generally Section 351 products.
-
California Senate Bill 1004 (2017, Health and Safety Code Section 1644.5)
Requires providers of non-FDA-approved stem cell therapies to post a notice to patients disclosing that the treatment has not been approved by the FDA. -
California Proposition 71 (2004) and Proposition 14 (2020), California Institute for Regenerative Medicine
Established and refunded CIRM to fund regenerative medicine research under strict scientific and ethical oversight. -
California Business and Professions Code Section 651
Prohibits false, misleading, or deceptive medical advertising, regularly cited in disciplinary actions against stem cell marketing. -
California Business and Professions Code Section 2052 (Medical Practice Act)
Governs physician licensure and prohibits unlicensed practice of medicine, including unauthorized administration of biologic injections.
California has been a focal point of federal enforcement. In United States v California Stem Cell Treatment Center (2022), the Ninth Circuit upheld FDA authority to regulate stromal vascular fraction as a Section 351 drug, resulting in a permanent injunction against the clinic. The FDA has issued multiple warning letters to California providers marketing stem cell and exosome therapies. The Medical Board of California has disciplined physicians for false advertising under BPC 651 and for administering unapproved biologics. The California Department of Public Health enforces tissue bank licensing. Class-action consumer suits against regenerative clinics have produced settlements.